RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%

Summary by AI BETAClose X

Recordati reported strong first-quarter 2026 results with net revenue up 4.9% to €713.4 million, driven by a 14.8% increase in Rare Diseases revenue, while EBITDA rose 5.0% to €283.6 million and adjusted net income grew 7.2% to €188.1 million. The company confirmed its full-year 2026 financial targets and announced positive Phase 2 trial results for pasireotide in post-bariatric hypoglycemia, with a meeting scheduled with the FDA. Additionally, sutimlimab will advance to a Phase 3 trial for chronic immune thrombocytopenia. Free cash flow decreased by €66.7 million to €92.1 million, and net debt stood at €1,985.2 million.

Disclaimer*

UK 100

Latest directors dealings